There are currently 91 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
NCT04925492
Recruiting
The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image VOC, using positron emission tomography (PET). The ability to see and measure VOC in SCD patients can help patient care, by showing when and how a VOC is occurring or going to occur. Studying this method will also help in future drug research, as it will allow researchers... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: UPMC, Pittsburgh, Pennsylvania
Conditions: Sickle Cell Disease
Register for Updates
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
NCT06313398
Recruiting
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant. Objective: To learn how long RBCs survive in the body in pe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Thalassemia, Hemoglobinopathy
Register for Updates
Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)
NCT05383911
Recruiting
This study will evaluate the acceptability, feasibility, and preliminary efficacy of a shared decision making intervention for adolescents and young adults (AYAs) with sickle cell disease (SCD). 60 AYAs with SCD ages 15-25 and their caregivers and 8 SCD providers will participate in the pilot pragmatic trial. AYAs, caregivers, and providers will be recruited from Nemours Children's Hospital, Delaware (NCH-DE), Nemours Children's Hospital in Orlando, FL (NCH-ORL), and Nemours Children's Health at... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/22/2025
Locations: Nemours Children's Hospital, Delaware, Wilmington, Delaware
Conditions: Sickle Cell Disease
Register for Updates
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
NCT05457790
Recruiting
Research Type: Clinical Trial Background: People with sickle cell disease (SCD) have many health challenges. Also, they often have trouble sleeping. Acceptance and commitment therapy (ACT) might help people with SCD to improve their sleep problems. Objective: To see how well ACT works in people with SCD and sleep problems and to find out how they feel about it. Eligibility: People between the ages of 18 and 55 with SCD and trouble sleeping. Design: The study is remote. Participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Register for Updates
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
NCT06635902
Recruiting
The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-al... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
04/14/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Register for Updates
Ultrasound Acute Chest Syndrome Sickle Cell Disease
NCT06880679
Recruiting
Feasibility and reliability of ultrasound in the inpatient hematology setting.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
04/09/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Acute Chest Syndrome, Sickle Cell Disease
Register for Updates
Tocilizumab for Acute Chest Syndrome
NCT05640271
Recruiting
The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigator... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Sickle Cell Disease, Acute Chest Syndrome
Register for Updates
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563
Recruiting
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
03/28/2025
Locations: Columbia University Medical Center, New York, New York +5 locations
Conditions: Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Anemia, Sickle Cell Disease
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, Phoenix, Arizona +72 locations
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Gene Editing For Sickle Cell Disease
NCT06506461
Recruiting
This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoieti... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
03/24/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
Gender:
ALL
Ages:
Between 12 years and 55 years
Trial Updated:
03/10/2025
Locations: Quotient Sciences Sea View, Miami, Florida
Conditions: Sickle Cell Disease
Register for Updates
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Recruiting
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
03/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Register for Updates